Blog

PTAB reverses obviousness rejection based on unpredictable results from site of deuteration

November 04, 2019

PTAB reverses Examiner’s finding of obviousness based on evidence distinguishing claimed insomnia population from insomnia population in the prior art.

October 20, 2019

Rosy predictions of cancer drug’s efficacy in a general review article did not impart reasonable expectation of success without data supporting the predictions.

October 14, 2019

Pharmacokinetic / dissolution claims save sustained release combination of naltrexone and bupropion from generic challenge.

September 30, 2019

Federal Circuit reversed district court decision to dismiss patent lawsuit at pleadings stage because dose adjustment required by claims was concrete application of natural law.

September 02, 2019

FDA clarifies requirements to be listed as the active ingredient in a drug product.

January 06, 2019

When will a preamble to a claimed method of treatment be given limiting effect? The answer might surprise you.

November 27, 2018

American patent rules seem to foreclose additional patent protection for new stereoisomers, while European patent rules offer some margin of hope.

June 24, 2018

Federal Circuit rules that eligibility for drug / diagnostic patent turns on distinction between manipulative steps and mental steps.

May 22, 2018

Patent claiming dose reduction for poor metabolizers affirmed at Federal Circuit.

April 22, 2018